By [Your Name/Editorial Staff], based on the work of Jana Wu, LCSW, LADC, ICAADC, CASAC
For over 15 years, Jana Wu has sat across from patients in the clinical trenches of mental health and substance use treatment. As she approaches her 50th year, a profound, systemic question has begun to overshadow her clinical practice: Why is the medical and therapeutic establishment so eager to "fix" or suppress women’s distress before truly understanding its root causes?
This question has been sharpened by the rising tide of kratom—a tropical tree leaf from Southeast Asia that has infiltrated the American market as a botanical supplement. Increasingly, women in their late 30s to early 60s are reporting the use of kratom not just for pain, but for the elusive promise of energy and emotional regulation. In a society that demands women be simultaneously high-performing employees, attentive mothers, and primary caregivers to aging parents, kratom is being utilized as a pharmacological "bridge" to sustain an unsustainable pace of life.
A Historical Echo: From Hysteria to "Mother’s Little Helper"
To understand the current attraction to kratom, one must look at the long, checkered history of how Western medicine has addressed female distress. The trend of pathologizing—and then medicating—the female experience is not a modern phenomenon.
The Evolution of the "Anxious Woman"
In the 19th century, the medical establishment relied on catch-all diagnoses like "hysteria" and "neurasthenia" to explain away a spectrum of symptoms: insomnia, fatigue, irritability, and chronic pain. By the mid-20th century, the diagnosis shifted, but the solution remained the same: chemical sedation.
The 1950s and 60s ushered in the era of "Mother’s Little Helper." Medications like Miltown and, later, Valium (introduced in 1963), became the go-to remedy for the domestic pressures of suburban life. The cultural resonance of this reliance was so profound that it was immortalized in 1966 by the Rolling Stones. Nearly 60 years later, while the specific medications have evolved from benzodiazepines to a variety of pharmaceutical and "natural" alternatives, the core issue remains stagnant: What happens when the underlying distress remains untouched?
The Midlife Crisis: A Perfect Storm for Dependence
For women in midlife, the current healthcare environment presents a perfect storm. Perimenopause and menopause trigger significant physiological shifts—including sleep disruption, hormonal instability, and heightened anxiety. When these biological factors collide with the "sandwich generation" phenomenon—where women are squeezed between the demands of young children and aging parents—the threshold for what is considered "manageable" distress drops significantly.
The Limitations of Symptom Management
Modern healthcare is often structurally designed to prioritize rapid symptom resolution over holistic inquiry. It is far more efficient to prescribe a sedative or recommend a supplement that "takes the edge off" than it is to engage in the time-consuming work of uncovering why a patient no longer feels at home in her own body.
True clinical care requires patience. It demands that a provider differentiate between situational stress, hormonal fluctuations, psychological trauma, and clinical pathology. When we bypass this inquiry, we are not treating the woman; we are merely managing her productivity.
The Kratom Phenomenon: Nature vs. Safety
Kratom has emerged as a distinct variable in this narrative. For many women, it represents a departure from the "pharmaceutical industrial complex." Because it is marketed as a natural, traditional botanical, it carries a psychological cachet of being safer or more "holistic" than a prescription pill.
However, clinicians like Wu warn that the distinction between "natural" and "safe" is a dangerous fallacy.
Key Risks and Regulatory Gaps
- Lack of Regulation: Unlike FDA-approved medications, kratom products in the U.S. exist in a regulatory gray area. There is no standardization for potency, meaning a user may consume drastically different concentrations of alkaloids in two different batches of the same product.
- Poly-Substance Risks: The most significant danger lies in what users take alongside kratom. Many individuals who come to treatment centers are combining kratom with alcohol, benzodiazepines, or opioids. This creates a cocktail of sedating agents that significantly increases the risk of respiratory depression, severe cognitive impairment, and dangerous physiological interactions.
- The Illusion of Control: For many women, choosing kratom is an attempt to reclaim agency over their own health. When traditional doctors offer only antidepressants or anti-anxiety medications—which may come with unwanted side effects like weight gain or "emotional blunting"—women may feel forced to seek alternatives.
Whose Discomfort Are We Treating?
The most challenging question for clinicians today is not how to stop the use of a specific substance, but rather, whose discomfort is being treated?
Often, the drive to medicate women is fueled by a societal discomfort with the outward manifestations of female distress. If a woman is tired, irritable, or struggling to maintain her "superwoman" status, the systems around her—employers, family members, and sometimes even medical providers—may subtly pressure her to return to her baseline functioning as quickly as possible.
The Clinical Imperative
Providers must transition from being "dispensers of relief" to "facilitators of understanding." This requires a radical shift in clinical practice:
- Active Listening: Clinicians must move beyond the intake form and ask, "What is this anxiety telling us about your life?"
- Trauma-Informed Care: Acknowledging that current symptoms may be linked to years of suppressed needs or unaddressed trauma.
- Beyond the Binary: Rejecting the false choice between enduring chronic pain/anxiety or masking it with substances. There is a third path: evidence-based, integrative care that addresses the whole person.
Implications for Future Research and Policy
The surge in kratom use is a symptom of a larger, systemic failure to support women through the transitions of midlife. As researchers continue to study kratom use disorder, the focus must shift toward the patient journey.
Recommendations for the Medical Community
- Increased Screening: Providers should screen for all substance use, including herbal supplements, with the same rigor they apply to pharmaceuticals.
- Support Systems: Developing support groups specifically for women struggling with substance use and midlife transitions. Wu’s work in founding the first clinician-led kratom support group serves as a model for how to build community-based, non-judgmental recovery spaces.
- Systemic Advocacy: Addressing the societal expectations that drive women toward constant, high-level performance. If the "distress" is caused by a life that is truly unmanageable, the treatment plan must include social and environmental changes, not just chemical ones.
Conclusion: A Call for Patience
Jana Wu’s perspective serves as a necessary wake-up call for the medical community. The history of women’s health is littered with stories of "quick fixes" that eventually led to deeper cycles of dependence. Kratom may be the latest chapter, but the underlying narrative—a woman searching for relief in a world that demands too much of her—is an old one.
As we move forward, the goal of medicine should not be to return women to a state of "functioning" as quickly as possible, but to help them find a sustainable, healthy way to live. The hardest, yet most necessary, work begins when we stop asking, "How can we make this symptom go away?" and start asking, "What does this woman need to thrive, rather than just survive?"
About the Contributor
Jana Wu, LCSW, LADC, ICAADC, CASAC, is a clinician at Mountainside Treatment Center. She specializes in PTSD, anxiety, depression, and co-occurring disorders. As a nationally recognized expert on kratom, she has spearheaded efforts to educate professionals on emerging substance use trends. Her work has been featured in The Wall Street Journal, Rolling Stone, and on NBC News, marking her as a leading voice in the call for more compassionate, patient-centered addiction care.
